David Roux, an analyst from Morgan Stanley, maintained the Buy rating on Glanbia. The associated price target is €16.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Roux has given his Buy rating due to a combination of factors that highlight Glanbia’s potential for growth and stability. One key aspect is the improvement in the Optimum Nutrition brand’s performance, which saw a positive shift in like-for-like sales, indicating a recovery and resilience in the market. This suggests that the brand is effectively navigating cost inflation challenges and could potentially regain market share through innovation and expansion into new channels and geographies.
Additionally, the Performance Nutrition segment is expected to maintain a mid-single-digit growth trajectory, which is a positive indicator for the company’s future revenue streams. The anticipated deflation in whey input costs and the strategic management of marketing expenditures further support the financial health and operational efficiency of Glanbia. These elements combined provide a solid foundation for a Buy rating, as they reflect both current strengths and future opportunities for the company.
According to TipRanks, Roux is ranked #9102 out of 9916 analysts.
In another report released yesterday, Barclays also maintained a Buy rating on the stock with a €16.25 price target.